Alnylam Pharmaceuticals Inc (ALNY) Company Profile & Statistics

Alnylam Pharmaceuticals Inc
ALNY
(Nasdaq - US)
Open
253.79
+0.63 (+0.25%)
in:usd•As of: Sep 10, 2024 09:43 UTC -4
Open
253.21
High
254.86
Low
253.21

About Alnylam Pharmaceuticals Inc

CEO

Yvonne L. Greenstreet

Headquarters

675 west kendall street, henri a. termeer square

cambridge, ma 02142, united states

Auditor

PricewaterhouseCoopers LLP

Employees

2,100

Share Holders

Website

www.alnylam.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..

Alnylam Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization ²	32.58B
Enterprise Value	32.64B
Enterprise Value/EBITDA (ttm)	162.91
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	13.51
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	86.37%
Operating Margin (ttm)	-3.11%
Profit Margin (ttm)	-6.89%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	-9.80%
Return on Assets (ttm)	-1.88%

Income Statement

Revenue (ttm)	2.34B
Revenue Per Share (ttm)	18.26
Gross Profit (ttm)	2.04B
EBITDA (ttm)³	200.32M
Net Income Avi to Common (ttm)	-72.94M
Diluted EPS (ttm)	-2.68

Share Statistics

Beta (5Y Monthly)	0.38
52-Week Change	24.58%
S&P500 52-Week Change	21.92%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	128.38M
Dividend Yield	0.00%
Float ⁴	124.59M
% Held by Insiders	1.50%
% Held by Institutions	92.97%

Balance Sheet

Total Cash (mrq)	2.62B
Total Cash Per Share (mrq)	20.44
Total Debt (mrq)	1.02B
Total Debt/Equity (mrq)	-33344.90%
Current Ratio (mrq)	3.01%
Quick Ratio (mrq)	2.93%
Book Value Per Share (mrq)	-0.02

Cash Flow

Operating Cash Flow Per Share (ytd)	0.34
Free Cash Flow (ytd)	21.65M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Alnylam Pharmaceuticals Inc

Trade With A Regulated Broker